{"id":"W4415442914","doi":"10.1182/bloodadvances.2025017731","title":"Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; University of Toronto","funders":"Janssen Pharmaceuticals; Samsung; Novo Nordisk; Agios Pharmaceuticals; Swedish Orphan Biovitrum; Apellis Pharmaceuticals; Omeros Corporation; BioCryst; Regeneron Pharmaceuticals; BeiGene; Sanofi; Celgene; AstraZeneca; Alexion Pharmaceuticals; Pfizer; Amgen","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Adverse effect; Clinical endpoint; Hemoglobinuria; Clinical trial; Anemia; Hemolysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005930537,0.0001169177,0.0002398114,0.00008097355,0.00005164019,0.000004976887,0.0001187153,0.00004371228,0.0001207151],"category_scores_gemma":[0.00002736292,0.00009122473,0.00002173278,0.0001203021,0.0001175282,0.00007473207,0.00003614214,0.00007175883,0.00000558565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001160076,"about_ca_system_score_gemma":0.00004299254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002987772,"about_ca_topic_score_gemma":0.0000377309,"domain_scores_codex":[0.9992709,0.00007996297,0.0002593293,0.0001961769,0.00003107717,0.0001626147],"domain_scores_gemma":[0.9995757,0.0001177903,0.0001083731,0.000152245,0.0000342475,0.00001161349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002850659,0.0005104693,0.9848322,0.00007284562,0.0001672192,0.000001272897,0.0001149274,0.00002030652,0.003054107,0.0004981036,0.00006590913,0.007811985],"study_design_scores_gemma":[0.01615268,0.0004473374,0.958294,0.0002888158,0.00005505512,0.000002403136,0.00009594575,2.492482e-7,0.01319333,0.0002416022,0.01110386,0.0001247156],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881885,0.01046573,0.00001156228,0.00004687662,0.0001414703,0.0003833024,0.00003144486,0.00001734764,0.000713778],"genre_scores_gemma":[0.9995015,0.0001094539,0.0000867857,0.00005445869,0.000005786427,0.00001601303,0.00002637732,0.000005441666,0.0001942214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02653819,"threshold_uncertainty_score":0.3720037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002885365793110706,"score_gpt":0.2313277992595405,"score_spread":0.2284424334664298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}